Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1770768210
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2130 W Holcombe Blvd, 10th Floor
Houston, TX, 77030
Phone (713) 600-0900
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
108,358 services
Medicare patients, 2024
341
Average age 74
Drug cost, 2024
$4.8M
2,081 prescriptions
Company payments, 2025
$377K
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Devesh M Pandya was code Q9967 (low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml), 8,875 times for 56 patients. In total Devesh M Pandya billed 108,358 services in 138 codes, and Medicare paid $2.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 8,875 | 56 | $0.10 | $894 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,542 | 17 | $0.09 | $230 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,740 | 19 | $0.76 | $1,316 |
| 85025 Blood Count | Office | 947 | 296 | $7.60 | $7,201 |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 840 | 15 | $112.09 | $94K |
| 99214 Office E&M - Established | Office | 551 | 247 | $90.42 | $50K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 419 | 228 | $12.75 | $5,344 |
| 96413 Chemotherapy Administration | Office | 246 | 27 | $96.86 | $24K |
| 96367 Intravenous Infusion, Hydration | Office | 243 | 20 | $20.96 | $5,093 |
| 96375 Injection Administration | Office | 204 | 19 | $11.54 | $2,355 |
| 96372 Injection Administration | Office | 144 | 26 | $10.53 | $1,516 |
| 99215 Office E&M - Established | Office | 141 | 78 | $131.16 | $18K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 120 | 18 | $4.39 | $526 |
| 80047 Clinical Chemistry | Office | 108 | 44 | $13.46 | $1,454 |
| 99211 Office E&M - Established | Office | 103 | 36 | $16.39 | $1,688 |
By year: 2022 $1.0M for 76,890 services; 2023 $822K for 99,131 services; 2024 $2.0M for 108,358 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 947 | 296 | $7.60 | $7,201 |
| 80047 Clinical Chemistry | 108 | 44 | $13.46 | $1,454 |
| 82565 Clinical Chemistry | 69 | 47 | $5.02 | $346 |
| 36415 Venipuncture Blood Collection | 30 | 24 | $8.65 | $260 |
Medicare prescription drug claims, 2024
In 2024, the drug Devesh M Pandya prescribed most often to Medicare patients was Letrozole, with 206 prescriptions and refills. In total Devesh M Pandya wrote 2,081 Medicare prescriptions that cost $4.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 206 | 521 | 67 | $5,211 |
| Dexamethasone Generic | 99 | 115 | 51 | $2,028 |
| Prednisone Generic | 92 | 108 | 30 | $377 |
| Gabapentin Generic | 91 | 135 | 35 | $1,046 |
| Eliquis Apixaban | 82 | 113 | 21 | $65K |
| Famciclovir Generic | 73 | 111 | 18 | $3,926 |
| Aprepitant Generic | 70 | 70 | 17 | $28K |
| Granisetron Hcl Generic | 69 | 69 | 55 | $18K |
| Neulasta Pegfilgrastim | 64 | 64 | 13 | $390K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 64 | 64 | 51 | $609 |
| Abiraterone Acetate Generic | 62 | 62 | 11 | $172K |
| Ondansetron Odt Ondansetron | 61 | 61 | 52 | $1,723 |
| Loperamide Loperamide Hcl | 56 | 56 | 39 | $696 |
| Atovaquone Generic | 53 | 53 | Under 11 | $31K |
| Exemestane Generic | 45 | 103 | 15 | $4,642 |
Brand drugs: 488 claims; generic drugs: 1,593 claims; opioid claims: 47.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Devesh M Pandya $377K ($377K in general payments such as food, travel and fees) from 28 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $74K.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 27 | $74K |
| Jazz Pharmaceuticals Inc. JAZZ | 60 | $72K |
| Gilead Sciences, Inc. GILD | 48 | $70K |
| GlaxoSmithKline, LLC. GSK | 30 | $41K |
| AstraZeneca Pharmaceuticals LP AZN | 29 | $31K |
| Pfizer Inc. PFE | 17 | $25K |
| Janssen Biotech, Inc. JNJ | 27 | $25K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $18K |
| Astellas Pharma US Inc 4503.T | 11 | $12K |
| Daiichi Sankyo Inc. 4568.T | 7 | $5,632 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.